ADALIMUMAB FOR MAINTENANCE THERAPY FOR ONE YEAR IN CROHN’S DISEASE: results of a Latin American single-center observational study
Context Adalimumab is a fully-human antibody that inhibits TNF alpha, with a significant efficacy for long-term maintenance of remission. Studies with this agent in Latin American Crohn’s disease patients are scarce. Objectives The objective of this study was to outline clinical remission rates after 12 months of adalimumab therapy for Crohn’s disease patients. Methods Retrospective, single-center, observational study of a Brazilian case series of Crohn’s disease patients under adalimumab therapy. Variables analyzed: demographic data, Montreal classification, concomitant medication, remission rates after 1, 4, 6 and 12 months. Remission was defined as Harvey-Bradshaw Index ≤4, and non-responder-imputation and last-observation-carried-forward analysis were used. The influence of infliximab on remission rates was analyzed by Fischer and Chi-square tests (P<0.05). Results Fifty patients, with median age of 35 years at therapy initiation, were included. Remission rates after 12 months of therapy were 54% under non-responder-imputation and 88% under last-observation-carried-forward analysis. After 12 months, remission on patients with previous infliximab occurred in 69.23% as compared to 94.59% in infliximab-naïve patients (P = 0.033). Conclusions Adalimumab was effective in maintaining clinical remission after 12 months of therapy, with an adequate safety profile, and was also more effective in infliximab naïve patients.
Main Authors: | KOTZE,Paulo Gustavo, ABOU-REJAILE,Vinícius Rezende, UIEMA,Luciana Aparecida, OLANDOSKI,Marcia, SARTOR,Maria Cristina, MIRANDA,Eron Fábio, KOTZE,Lorete Maria da Silva, SAAD-HOSSNE,Rogério |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia e Outras Especialidades - IBEPEGE.
2014
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032014000100039 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative analysis of adverse events between infliximab and adalimumab in Crohn's disease management: a Brazilian single-centre experience
by: Kotze,Paulo Gustavo, et al.
Published: (2013) -
SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN’S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB
by: BAU,Mariella, et al.
Published: (2017) -
Adalimumab in the induction of Crohn's disease remission: results of a Brazilian multicenter case series
by: Kotze,Paulo Gustavo, et al.
Published: (2011) -
Reindução da remissão clínica com adalimumabe após interrupção do tratamento: uma alternativa no manejo da doença de Crohn
by: Kotze,Paulo Gustavo, et al.
Published: (2010) -
Complications after intestinal resection in Crohn's disease: laparoscopic versus conventional approach
by: Kotze,Paulo Gustavo, et al.
Published: (2013)